The estimated Net Worth of Konstantinos Xynos is at least $1.47 millió dollars as of 7 June 2024. Konstantinos Xynos owns over 15,881 units of Replimune Inc stock worth over $1,214,648 and over the last 2 years Konstantinos sold REPL stock worth over $254,077.
Konstantinos has made over 4 trades of the Replimune Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Konstantinos sold 15,881 units of REPL stock worth $119,108 on 7 June 2024.
The largest trade Konstantinos's ever made was selling 15,881 units of Replimune Inc stock on 7 June 2024 worth over $119,108. On average, Konstantinos trades about 4,333 units every 55 days since 2022. As of 7 June 2024 Konstantinos still owns at least 117,131 units of Replimune Inc stock.
You can see the complete history of Konstantinos Xynos stock trades at the bottom of the page.
Konstantinos's mailing address filed with the SEC is C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, SUITE 303, WOBURN, MA, 01801.
Over the last 6 years, insiders at Replimune Inc have traded over $72,652,546 worth of Replimune Inc stock and bought 2,360,000 units worth $33,565,200 . The most active insiders traders include Group, Llc Green Jeremy Red..., Capital Life Sciences Inves... és Jason P Rhodes. On average, Replimune Inc executives and independent directors trade stock every 21 days with the average trade being worth of $508,649. The most recent stock trade was executed by Emily Luisa Hill on 16 August 2024, trading 8,938 units of REPL stock currently worth $90,989.
replimune group, inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. it uses its proprietary immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. the company's lead product candidate is rp1, a selectively replicating version of herpes simplex virus 1, which is in phase i/ii clinical trials for a range of solid tumors; and that is in phase ii clinical trials for patients with cutaneous squamous cell carcinoma. it is also developing rp2, which is in phase i clinical trials for an anti-ctla-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by ctla-4; and rp3 to express immune-activating proteins that stimulate t cells. replimune group, inc. was founded in 2015 and is headquartered in woburn, massachusetts.
Replimune Inc executives and other stock owners filed with the SEC include: